Key highlights:

• FY26 statutory revenue is expected to land between A$56 million and A$58 million, down roughly 17% on the prior year, with the group guiding to an EBITDA loss of A$2.0 million to A$4.0 million.

• The group closed FY26 with A$51.7 million in cash, up 27% year on year, a balance that roughly equals the company's entire market capitalisation of approximately A$52 million at mid-2026 share prices.

• Management attributed the shortfall to softer renewals, a first-half new-business burst that did not carry through to the second half, and deals deferred into FY27, as AI-driven caution slowed enterprise technology spending.

There is irony in a company that sells software to keep the world's most critical systems running having to steady its own ship. Integrated Research (ASX:IRI), the Sydney-based maker of performance-monitoring tools trusted by major banks and telcos, delivered a sobering trading update on 24 July 2026. Revenue for the year to 30 June is expected to land between A$56 million and A$58 million, down roughly 17% on the prior year, and the group has guided to an EBITDA loss where a solid profit once sat.

Yet the reaction has been measured rather than panicked. Beneath the softer top line sits a transformed balance sheet: IRI ended the year with A$51.7 million in cash, up 27% year on year and close to the company's entire stock-market value. For a business mid-reset, that cushion is the difference between a crisis and a project.

Company Overview

Integrated Research has spent more than 35 years building software that watches over mission-critical infrastructure. Its Prognosis platform underpins a suite organised around three pillars: Collaborate, monitoring unified communications and contact centres; Transact, analysing high-value, card and real-time payments; and Infrastructure, keeping back-end systems healthy.

Its customers read like a who's-who of global enterprise: Vodafone, HCL and Woolworths Group among them. More recently, IRI has leaned into AI with Iris, a natural-language observability layer, and Elevate, a platform-as-a-service model designed to shift customers towards recurring, cloud-based consumption. That pivot from perpetual licences to a product-led motion sits at the heart of both the current pain and the prize.

Latest News

The unaudited FY26 trading update, released on 24 July 2026, confirmed statutory revenue of A$56-58 million against A$68.3 million a year earlier, with pro forma revenue of A$64-66 million versus A$74.3 million in FY25 - a decline of around 13% at the midpoint.

Chief executive Ian Lowe framed it as a turning point, not a retreat. "FY26 was a pivotal year as IR advanced its product-led growth execution," he said, adding that "with AI driving more cautious technology investment decisions, accelerating monetisation of new products and expanding client-led innovation are key priorities for FY27." It was candid about the causes: a softer renewals book, a first-half new-business burst that failed to carry into the second half, and deals slipping into FY27 - all still unaudited.

Why Investors Are Watching

The central question is whether IRI is a value trap or a coiled spring. On the bear side, a 17% revenue slide and a swing to losses are not signals to wave away, and the stock has fallen more than a third over the past year to a 52-week low around A$0.27.

On the bull side, cash worth nearly the whole market value gives an enormous margin of safety, funding development and returning capital without tapping equity markets on poor terms. For deep-value investors, that mix of a beaten-down price, a fortress balance sheet and a genuine pivot rewards patience if execution improves.

Growth Opportunities

The clearest path back to growth runs through newer, cloud-oriented products. Elevate and the Iris AI observability layer are designed to lift recurring revenue and convert an installed base with deep Prognosis ties into steadier subscription income, smoothing the lumpy licence revenue that made FY26 volatile.

The payments franchise is another lever: as real-time payment rails proliferate, demand for independent transaction monitoring should structurally rise. Management has pointed to deals deferred into FY27, implying a pipeline delayed rather than lost.

Risks

The risks are real and immediate. A shrinking top line paired with an operating loss puts the onus on management to reignite growth before the cash cushion is drawn down. Customer churn outpacing new business is the most worrying dynamic; if renewals keep softening, the base could erode further before the pivot bears fruit.

External pressures compound this. The company noted AI is prompting enterprises to be more cautious with technology spending - a double-edged sword for a firm betting on AI-enabled products. The foreign-exchange and expected-credit-loss pressures that hit FY26 earnings could recur, and sustained losses would erode the very asset that gives investors comfort.

Industry Outlook

The broader observability and performance-monitoring market remains structurally attractive. As enterprises run complex, multi-vendor, hybrid-cloud estates, the cost of downtime climbs and the value of software that detects issues early rises with it.

Generative AI is also reshaping how organisations buy technology: budgets are being redirected towards AI experimentation and buyers are scrutinising every line item - the very caution IRI's chief executive highlighted. Vendors that embed AI into their own products, as IRI is attempting with Iris, stand to benefit most.

What to Watch Next

The immediate catalyst is IRI's audited full-year results, confirming the guidance and revealing cash-flow detail and any dividend change. Watch the recurring-versus-one-off revenue split, the pace of Elevate and Iris adoption, and commentary on the FY27 pipeline.

Beyond the numbers, the signals are whether deferred deals convert in H1 FY27, whether renewals stabilise, and whether the EBITDA loss proves a one-year reset or a longer decline.

Conclusion

Integrated Research's FY26 looks ugly: revenue down 17%, a swing to an EBITDA loss and a share price near multi-year lows. But the story is more nuanced: this is a recently profitable software business with entrenched, blue-chip customers, a credible AI-led pivot and, above all, a A$51.7 million cash balance that buys the time most turnarounds never get.

The verdict now rests on execution. If management can convert its deferred pipeline, arrest churn and push newer products into the installed base, today's valuation may look a rare bargain in hindsight. Either way, IRI is worth following - a company selling resilience to the world, now proving whether it can engineer its own. This article is editorial commentary and general information only, not investment advice.